Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy (Breast Cancer Research, (2013), 15, 6, (R118), 10.1186/bcr3587);Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy

Breast Cancer Research

Volumn 15, Issue 6, 2013, Pages

  Díaz Flaqué, María C ^a   Galigniana, Natalia M ^a   Béguelin, Wendy ^a   Vicario, Rocío ^a   Proietti, Cecilia J ^a   Russo, Rosalía C ^a   Rivas, Martín A ^a   Tkach, Mercedes ^a   Guzmán, Pablo ^b   Roa, Juan C ^b   Maronna, Esteban ^a,c   Pineda, Viviana ^b   Muñoz, Sergio ^b   Mercogliano, María F ^a   Charreau, Eduardo H ^a   Yankilevich, Patricio ^d   Schillaci, Roxana ^a   Elizalde, Patricia V ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c Sanatorio Mater Dei   (Argentina)

^d Instituto de Investigación en Biomedicina de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ENHANCEOSOME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; STAT3 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; CCND1 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MEDROXYPROGESTERONE ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; COHORT ANALYSIS; DRUG MECHANISM; DRUG RESISTANCE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TREATMENT RESPONSE; TUMOR GROWTH; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL NUCLEUS; DRUG EFFECTS; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANIMALS; BREAST NEOPLASMS; CELL NUCLEUS; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDROXYPROGESTERONE ACETATE; MICE, INBRED BALB C; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STAT3 TRANSCRIPTION FACTOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; TREATMENT OUTCOME;

EID: 84890285957     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-023-01735-z     Document Type: Erratum

References (79)

1. Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab 2011, 6:359-369. 10.1586/eem.11.25, 3156468, 21857868.
2. Balana ME, Lupu R, Labriola L, Charreau EH, Elizalde PV. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene 1999, 18:6370-6379. 10.1038/sj.onc.1203028, 10597237.
3. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998, 17:2008-2018. 10.1093/emboj/17.7.2008, 1170546, 9524123.
4. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001, 8:269-280. 10.1016/S1097-2765(01)00304-5, 11545730.
5. Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier JE, Schillaci R, Elizalde PV. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 2007, 21:1335-1358. 10.1210/me.2006-0304, 17440047.
6. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 2005, 25:4826-4840. 10.1128/MCB.25.12.4826-4840.2005, 1140598, 15923602.
7. Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Diaz Flaque MC, Charreau EH, Schillaci R, Elizalde PV. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 2009, 29:1249-1265. 10.1128/MCB.00853-08, 2643818, 19103753.
8. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 2007, 21:359-375. 10.1210/me.2006-0337, 17138644.
9. Beguelin W, Diaz Flaque MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 2010, 30:5456-5472. 10.1128/MCB.00012-10, 2976427, 20876300.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
11. Faivre E, Skildum A, Pierson-Mullany L, Lange CA. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 2005, 70:418-426. 10.1016/j.steroids.2005.02.012, 15862825.
12. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 1998, 273:10696-10701. 10.1074/jbc.273.17.10696, 9553133.
13. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol 2006, 26:7632-7644. 10.1128/MCB.00326-06, 1636875, 17015480.
14. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995, 270:23589-23597. 10.1074/jbc.270.40.23589, 7559524.
15. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987, 49:729-739. 10.1016/0092-8674(87)90611-8, 3034432.
16. Alkhalaf M, Murphy LC. Regulation of c-jun and jun-B by progestins in T-47D human breast cancer cells. Mol Endocrinol 1992, 6:1625-1633.
17. Morton S, Davis RJ, McLaren A, Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003, 22:3876-3886. 10.1093/emboj/cdg388, 169061, 12881422.
18. Monje P, Marinissen MJ, Gutkind JS. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol Cell Biol 2003, 23:7030-7043. 10.1128/MCB.23.19.7030-7043.2003, 193921, 12972619.
19. Gilley R, March HN, Cook SJ. ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos. Cell Signal 2009, 21:969-977. 10.1016/j.cellsig.2009.02.006, 19249353.
20. Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 2005, 24:6516-6524.
21. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 2001, 20:2771-2780. 10.1038/sj.onc.1204377, 11420689.
22. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002, 21:7680-7689. 10.1038/sj.onc.1205883, 12400010.
23. Schillaci R, Salatino M, Cassataro J, Proietti CJ, Giambartolomei GH, Rivas MA, Carnevale RP, Charreau EH, Elizalde PV. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. J Immunol 2006, 176:3426-3437.
24. Schillaci R, Guzman P, Cayrol F, Beguelin W, Diaz Flaque MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 2012, 12:74. 10.1186/1471-2407-12-74, 3342900, 22356700.
25. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636. 10.1200/JCO.2002.02.026, 12202663.
26. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let's do it. Am J Clin Pathol 1995, 103:123-124.
27. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919. 10.1158/1078-0432.CCR-07-0701, 17699871.
28. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 2012, 14:R77. 10.1186/bcr3187, 3446340, 22583478.
29. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-Jun. Oncogene 1993, 8:877-886.
30. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997, 272:18586-18594. 10.1074/jbc.272.30.18586, 9228025.
31. Giri DK, Ali-Seyed M, Li LY, Lee DF, Ling P, Bartholomeusz G, Wang SC, Hung MC. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol 2005, 25:11005-11018. 10.1128/MCB.25.24.11005-11018.2005, 1316946, 16314522.
32. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 1993, 7:1256-1265.
33. Ferreira T, Rasband W. ImageJ User Guide IJ 1.46r. [http://imagej.nih.gov/ij/docs/guide].
34. Bailey TL, Gribskov M. Combining evidence using p-values: application to sequence homology searches. Bioinformatics 1998, 14:48-54. 10.1093/bioinformatics/14.1.48, 9520501.
35. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics 2011, 27:1017-1018. 10.1093/bioinformatics/btr064, 3065696, 21330290.
36. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, Valen E, Yusuf D, Lenhard B, Wasserman WW, Sandelin A. JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 2010, 38:D105-D110. 10.1093/nar/gkp950, 2808906, 19906716.
37. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006, 34:D108-D110. 10.1093/nar/gkj143, 1347505, 16381825.
38. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004, 6:251-261. 10.1016/j.ccr.2004.07.012, 15380516.
39. Clarke CL, Graham JD. Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 2012, 7:e35859. 10.1371/journal.pone.0035859, 3335806, 22545144.
40. Machanick P, Bailey TL. MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 2011, 27:1696-1697. 10.1093/bioinformatics/btr189, 3106185, 21486936.
41. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh ID, To TV, Qian Z, Love RR, Allred DC. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004, 17:1545-1554. 10.1038/modpathol.3800229, 15272277.
42. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007, 165:710-718. 10.1093/aje/kwk052, 17182981.
43. Quiles I, Millan-Arino L, Subtil-Rodriguez A, Minana B, Spinedi N, Ballare C, Beato M, Jordan A. Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 2009, 23:809-826. 10.1210/me.2008-0454, 19299443.
44. Ginsberg M, Czeko E, Muller P, Ren Z, Chen X, Darnell JE. Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-Jun and c-Fos. Mol Cell Biol 2007, 27:6300-6308. 10.1128/MCB.00613-07, 2099614, 17636030.
45. Lerner L, Henriksen MA, Zhang X, Darnell JE. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev 2003, 17:2564-2577. 10.1101/gad.1135003, 218150, 14522952.
46. Zugowski C, Lieder F, Muller A, Gasch J, Corvinus FM, Moriggl R, Friedrich K. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem 2011, 392:449-459.
47. Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Dosne PC. Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 1990, 17:33-43. 10.1007/BF01812682, 2151368.
48. Simian M, Molinolo A, Lanari C. Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol 2006, 168:270-279. 10.2353/ajpath.2006.050012, 1592671, 16400029.
49. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009, 16:333-350. 10.1677/ERC-08-0244, 19190078.
50. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 2000, 89:177-186. 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0, 10754497.
51. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003, 23:1994-2008. 10.1128/MCB.23.6.1994-2008.2003, 149459, 12612073.
52. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 1999, 18:2500-2510. 10.1093/emboj/18.9.2500, 1171332, 10228164.
53. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361. 10.1093/jnci/95.5.353, 12618500.
54. Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 2005, 56:39-46.
55. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476. 10.1200/JCO.2005.01.172, 15753463.
56. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Kostler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008, 113:1294-1301. 10.1002/cncr.23689, 18661530.
57. Lebedeva G, Yamaguchi A, Langdon SP, Macleod K, Harrison DJ. A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. BMC Syst Biol 2012, 6:138. 10.1186/1752-0509-6-138, 3573949, 23134774.
58. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 2002, 57:295-316. 10.1210/rp.57.1.295, 12017549.
59. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 1984, 20:1419-1424. 10.1016/0277-5379(84)90062-2, 6542011.
60. Wakeling AE, Newboult E, Peters SW. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 1989, 2:225-234. 10.1677/jme.0.0020225, 2665780.
61. Chen B, Wang Y, Kane SE, Chen S. Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells. J Mol Endocrinol 2008, 41:367-377. 10.1677/JME-08-0026, 3503452, 18768663.
62. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011, 13:R121. 10.1186/bcr3067, 3326563, 22123186.
63. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997, 11:657-666. 10.1210/mend.11.6.0009, 9171229.
64. Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, Horwitz KB. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999, 69:45-50. 10.1016/S0960-0760(98)00148-4, 10418980.
65. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. J Steroid Biochem Mol Biol 2000, 74:255-259. 10.1016/S0960-0760(00)00101-1, 11162933.
66. Genomatix genome analyser - MatInspector. http://www.genomatix.de.
67. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002, 277:5209-5218. 10.1074/jbc.M110090200, 11717311.
68. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004, 24:7260-7274. 10.1128/MCB.24.16.7260-7274.2004, 479712, 15282324.
69. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999, 18:6063-6070. 10.1038/sj.onc.1202989, 10557095.
70. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59. 10.1186/1471-2407-7-59, 1852565, 17407600.
71. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999, 5:251-256.
72. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 2003, 17:628-642. 10.1210/me.2002-0378, 12554776.
73. Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol 2003, 23:1095-1111. 10.1128/MCB.23.3.1095-1111.2003, 140689, 12529413.
74. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004, 10:3621-3628. 10.1158/1078-0432.CCR-0740-3, 15173068.
75. McGowan EM, Russell AJ, Boonyaratanakornkit V, Saunders DN, Lehrbach GM, Sergio CM, Musgrove EA, Edwards DP, Sutherland RL. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 2007, 67:8942-8951. 10.1158/0008-5472.CAN-07-1255, 17875737.
76. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat 2008, 112:475-488. 10.1007/s10549-008-9897-4, 18327671.
77. Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer 2003, 89:1920-1926. 10.1038/sj.bjc.6601398, 2394433, 14612904.
78. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65:8009-8016.
79. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21:1973-1979. 10.1200/JCO.2003.09.099, 12743151.